StockNews.AI
ASBP
StockNews.AI
152 days

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

1. Aspire Biopharma completed GMP Clinical Batch for its fast-acting aspirin. 2. FDA submission support data is expected from upcoming bioavailability study.

3m saved
Insight
Article

FAQ

Why Bullish?

The completion of GMP batch and fast-track FDA submission signify positive advancements, akin to successful drug approvals boosting related stocks historically.

How important is it?

The FDA application and fast-track request can directly influence ASBP’s market perception and pricing.

Why Long Term?

If approval is granted after bioavailability results, ASBP could see significant growth, similar to other pharma stocks post-approval.

Related Companies

PFEMRKJNJ
Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire intends to request "fast track" approval on FDA application for its high dose aspirin product   HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent pending drug delivery technology, today announced that it its contract manufacturer, Glatt Air Techniques, Inc., part of Glatt Group, a vertically integrated pharmaceutical services company with FDA- and EU-approved sites, has completed its first Good Manufacturing Practice ("GMP") Clinical Batch of its pharmaceutical-grade oral mucosal formulation of aspirin that utilizes Aspire's fast-acting formulation. Aspire's GMP extracts are set to be administered in a bioavailability study in healthy human volunteers in April 2025.

Related News